Our pipeline
A portfolio built from what biology reveals.
TenSixty is advancing a platform-derived oncology portfolio with programs spanning discovery, lead optimization, and early IND-enabling work.
Pipeline of epitope-defined oncology therapeutics
One program in early IND-enabling work, a second in lead optimization, and multiple platform-derived binder programs.
-
Current work: early IND-enabling, including xenograft efficacy, NHP safety, and CMC progress
-
Current work: lead optimization and format selection
-
Current work: advancing through target validation and early optimization.
-
Current work: discovery queue
- 01 Target + epitope definition
- 02 Binder series
- 03 Biological validation
- 04 Lead optimization
- 05 Therapeutic formatting
- 06 Efficacy + safety
- 07 IND-enabling
- 08 Clinic
Investigational notice: All programs described on this page are investigational and have not been approved by any regulatory authority. Development-stage descriptions are qualitative, may change, and do not establish safety, efficacy, or the timing or likelihood of approval. Visual stage tracks show relative stage only; they are not timelines or probability estimates. Program descriptions, development objectives, and timing reflect current plans and may change.
Connect with TenSixty